Literature DB >> 12393552

Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia.

Stuart Lanham1, Terry Hamblin, David Oscier, Rachel Ibbotson, Freda Stevenson, Graham Packham.   

Abstract

The mutational status of tumor immunoglobulin V(H) genes is providing a powerful prognostic marker for chronic lymphocytic leukemia (CLL), with patients having tumors expressing unmutated V(H) genes being in a less favorable subset. However, the biologic differences correlating with V(H) gene status that could determine the clinical course of the disease are unknown. Here we show that differing responses to IgM ligation are closely associated with V(H) gene status. Specifically, 80% of cases with unmutated V(H) genes showed increased global tyrosine phosphorylation following IgM ligation, whereas only 20% of samples with mutated V(H) genes responded (P =.0002). There was also an association between response to IgM ligation and expression of CD38 (P =.015). The Syk kinase, critical for transducing B-cell receptor (BCR)- derived signals, was constitutively present in all CLL samples, and there was a perfect association between global phosphorylation and induction of phosphorylation/activation of Syk. Nonresponsiveness to anti-IgM could be circumvented by ligation of IgD (10 of 15 samples tested) or the BCR-associated molecule CD79alpha (12 of 15 samples tested). These results suggest that multiple mechanisms underlie nonresponsiveness to anti-IgM in CLL and that retained responsiveness to anti-IgM contributes to the poor prognosis associated with the unmutated subset of CLL. The prognostic power of the in vitro response to IgM ligation remains to be determined in a large series, but the simple technology involved may present an alternative or additional test for predicting clinical course.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393552     DOI: 10.1182/blood-2002-06-1822

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  91 in total

1.  Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.

Authors:  Kwan-Ki Hwang; Xi Chen; Daniel M Kozink; Marietta Gustilo; Dawn J Marshall; John F Whitesides; Hua-Xin Liao; Rosa Catera; Charles C Chu; Xiao-Jie Yan; Micah A Luftig; Barton F Haynes; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-12-12       Impact factor: 22.113

Review 2.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

3.  Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia.

Authors:  Fabio Ghiotto; Franco Fais; Angelo Valetto; Emilia Albesiano; Shiori Hashimoto; Mariella Dono; Hideyuki Ikematsu; Steven L Allen; Jonathan Kolitz; Kanti R Rai; Marco Nardini; Anna Tramontano; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 4.  CD23/FcεRII: molecular multi-tasking.

Authors:  M Acharya; G Borland; A L Edkins; L M Maclellan; J Matheson; B W Ozanne; W Cushley
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

Review 5.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

6.  Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

Authors:  Yuh-Ying Yeh; Hatice Gulcin Ozer; Amy M Lehman; Kami Maddocks; Lianbo Yu; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 7.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

8.  Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Int J Cancer       Date:  2017-08-04       Impact factor: 7.396

9.  Metadherin contribute to BCR signaling in chronic lymphocytic leukemia.

Authors:  Pei-Pei Li; Qing-Min Yao; Hui Zhou; Li-Li Feng; Xue-Ling Ge; Xiao Lv; Na Chen; Kang Lu; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 10.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.